Investing.com - Abbott Labs (NYSE: ABT) reported third quarter EPS of $1.21, $0.01 better than the analyst estimate of $1.20. Revenue for the quarter came in at $10.6B versus the consensus estimate of $10.56B.
Guidance
Abbott Labs sees Q4 2024 EPS of $1.31-$1.37 versus the analyst consensus of $1.34.
Abbott Labs's stock price closed at $116.05. It is up 13.74% in the last 3 months and up 25.95% in the last 12 months.
Abbott Labs saw 5 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Abbott Labs's stock price’s past reactions to earnings here.
According to InvestingPro, Abbott Labs's Financial Health score is "good performance".
Check out Abbott Labs's recent earnings performance, and Abbott Labs's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar